The Food and Drug Administration is warning doctors not to give probiotics to preterm infants.
The Food and Drug Administration is now warning hospitals not to give probiotics to preterm infants, after a baby was killed by bacteria linked to a probiotic.published
It is not clear which hospital administered the probiotic now being investigated by the FDA. An agency spokesperson did not immediately respond to a request for comment., Infinant Health had claimed its Evivo probiotic is"widely used by parents" as well as in hospitals and neonatal intensive care units"throughout the U.S."
"For parents asking, 'Should I give my baby probiotics?' note that 80% of our immune system is in our gut. It's imperative to care for your baby's gut microbiome today to give them a strong foundation for good health," the company says.that the product can be started"right after birth" alongside breast milk.
"Evivo is a food for special dietary use, meeting all FDA regulations for food products, and has been used by parents, hospitals and providers for five years with over 4.7 million feedings to date in over 60,000 babies," the company said in its May news release.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly Gets FDA Letter About Eczema Drug ConcernsThe pharmaceutical company says the letter cited no worries about the safety of its lebrikizumab skin treatment.
Read more »
Eli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facilityEli Lilly & Co. said Monday the U.S. Food and Drug Administration has issued a complete response letter for its lebrikizumab, a treatment for...
Read more »
Council Post: Tackling The Impending DSCSA Readiness Hurdles With A More Integrated Tech ApproachIn light of the FDA’s Drug Supply Chain Security Act, many pharma manufacturers still find themselves grappling with the intricacies of compliance.
Read more »
Eli Lilly Gets FDA Letter About Eczema Drug Concerns. The Stock Shrugs.The pharmaceutical company says the letter cited no worries about the safety of its lebrikizumab skin treatment.
Read more »
Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressivaA multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva (FOP).
Read more »